In our study, we found that the BRAF mutated cells, including HT29 and RKO cells, had relative higher IC50 of cetuximab than the KRAS/BRAF WT cells, Difi and Lim1215 cells (Fig. 1g), which indicated that BRAF mutation also contributes to the anti-EGFR antibodies resistance in CRC cells. The gene discussed is BRAF; the disease is colorectal carcinoma.